Pfizer threatened with product-hopping fine in Chile

Pfizer’s Chilean subsidiary could face a near US$20,000 fine after Chile’s competition enforcer requested that the country’s competition court impose the heaviest possible punishment for alleged abusive practices related to a drug patent.

Get unlimited access to all Latin Lawyer content